CD4 and cancer: On the one hand, CD4+ T cells (52), CD8+ T cells (53), and activated NK cells (54) play crucial roles in the TME, and they are essential for orchestrating immune responses and can promote immunity, influencing the efficiency of cancer immunotherapy.